Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is an operative clause of 21 CFR 202.1(e)(6)(iii), which declares a prescription drug advertisement false/lacking in fair balance/otherwise misleading if it 'contains literature references or quotations that are significantly more favorable to the drug than has been demonstrated by substantial evidence or substantial clinical experience.' This is a prohibition, not an example or definition, and the rule statement follows from it.
- Atomic: subparagraph (iii) contains two separate prohibitions (favorable information rendered invalid by more credible recent information; over-favorable literature references/quotations). The rule cleanly isolates the second and does not bundle the first.
- Determinism correctly set to judgment: 'significantly more favorable' requires comparing the tenor of cited literature against substantiation, which turns on degree and impression, not presence/absence or literal match.
- Authority correctly set to binding: 21 CFR 202.1 is a codified regulation.
- Severity 'blocker' is defensible: items under (e)(6) are per se false, lacking in fair balance, or otherwise misleading and violative of section 502(n), in contrast with the 'may be' items enumerated under (e)(7).
- Locator 21 CFR 202.1(e)(6)(iii) matches the quoted text exactly.
- Defect 1 (evidentiary standard misstated): the rule statement says 'substantial evidence or clinical experience,' dropping 'substantial' from the regulation's defined term 'substantial clinical experience' (defined at (e)(4)(ii)(c) as experience 'adequately documented in medical literature or by other data'). Lowering the comparator baseline broadens what would count as a violation.
- Defect 2 (missing scope limit): the source provision opens 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading...' The rule's applies_when of bare 'promotional' extends the obligation to all promotional material for any product class, dropping a limit that is explicit in the source.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is operative regulatory text, not an example or definition: it is the second clause of 21 CFR 202.1(e)(6)(iii), governed by the chapeau 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it:'. The rule statement follows directly from that framing.
- Not overstated. The source treats the described conduct as a per se violation of section 502(n), so rendering it as a prohibition ('may not contain') rather than a recommendation is faithful; there is no 'should'/'recommends' being upgraded, and no 'may be misleading' being converted to 'is prohibited' (that language belongs to paragraph (e)(7), which the rule does not draw on).
- Scope is correctly preserved: the rule statement is limited to advertisements for prescription drugs, matching the source's own scoping sentence. The parenthetical gloss of 'substantial evidence or substantial clinical experience' by reference to (e)(4)(ii)(b) and (c) mirrors the express cross-reference used in the parallel subparagraph (e)(6)(i) and does not broaden the obligation.
- Atomic: (e)(6)(iii) states two independent prongs (favorable information rendered invalid by more credible recent information; and literature references/quotations significantly more favorable than the evidence). The rule isolates the second prong and quotes only that clause, so it is a single independently checkable requirement.
- Determinism correctly set to 'judgment': 'significantly more favorable' requires a comparative assessment of degree between the tenor of cited literature and the supporting evidence base; presence/absence or literal matching cannot settle it. The escalate-when condition accurately captures the modest-gap and mixed-evidence cases.
- Authority correctly 'binding': 21 CFR 202.1 is a codified FDA regulation, and the provision defines a violation of section 502(n) of the Act.
- Severity 'blocker' is defensible because the source deems such an advertisement false, lacking in fair balance, or otherwise misleading as a matter of regulation, not a matter of presentational preference.
- Locator 21 CFR 202.1(e)(6)(iii) is exact; the quoted sentence appears verbatim at that subparagraph in the source text.
- Minor, non-blocking observations: applies_when uses 'drug' rather than 'prescription drug', but the prescription-drug limit is carried in the rule statement itself, and the source expressly extends to veterinary drugs, so the coarse value is not under-inclusive. The closing proviso to (e)(6) allows FDA to waive any provision of the paragraph for a specified advertisement on petition; this is an agency-granted exception to a flat prohibition and does not alter what a reviewer checks.